

1 on a current fund
last 24 months
across filed funds
| Vehicle | Filed | Target | Sold to date | Investors |
|---|---|---|---|---|
| Alta Partners NextGen Fund IVFiled to raise in 2023, with no closing reported yet. | 2023 | $250M | $0 | 0 |
| Alta Partners NextGen Fund IIIFiled to raise in 2021, with no closing reported yet. | 2021 | $250M | $0 | 0 |
| Alta Partners NextGen Fund IIFiled to raise in 2019, with no closing reported yet. | 2019 | $150M | $0 | 0 |
| Alta Partners IXFiled to raise in 2017, with no closing reported yet. | 2017 | $200M | $0 |
Amounts are Item 13 as filed: the target is the whole offering, and the amount sold is cumulative across amendments rather than a final close. The filing carries no per-investor amount, so a firm’s own cheque is not recoverable here.
4 partners are named across this firm’s filings, 1 of them on a fund it is deploying now.
| Partner | Activity | Categories | Board seats | Last 24mo |
|---|---|---|---|---|
| Pete HudsonNot on the current fund | Slowing | Digital health, Healthcare services, Enterprise software | 5 |
Categories of Alta Partners’s own portfolio companies, based on 25 with a verified or cited source.
| Firm | Shared boards | Companies |
|---|---|---|
| ARCH Venture Partners | 3 | Ally Therapeutics, eGenesis, Vir Biotechnology |
| Aditum Bio | 1 | eGenesis |
| Bain Capital Life Sciences | 1 | Affinivax |
| Dimension Capital |
| 0 |
| 1 |
| Bob MoreNot on the current fund | Quiet | Biotech & pharma, Food & agriculture, Medical devices | 11 | 0 |
| Daniel Janney | Quiet | Biotech & pharma, Medical devices | 9 | 0 |
| Larry RandallNot on the current fund | Quiet | None listed | 0 | 0 |
Activity is filed board seats in the last 24 months: 4+ Active, 2–3 Selective, 1 Slowing, none Quiet. A firm's tier totals its partners, so an active firm may be four partners with one seat each. It undercounts partners who invest without taking a board seat, and filings lag a closing by weeks, so Quiet means the paperwork is quiet, not the person.
Not a filing value: this is Lev’s own classification of each company, one company one vote regardless of how many of Alta Partners’s partners are named on its board, shown only when we found a specific, checkable source. Companies with no source read as unclassified and are left out of the shares above.
| 1 |
| Variant Bio |
| Energy Impact Partners | 1 | Evolve Biosystems |
| HealthX Ventures | 1 | Hunger Not Impossible |
| Longitude Capital | 1 | Esperion Therapeutics |
| Lux Capital | 1 | Variant Bio |
| NEA | 1 | Allakos |
| Oak HC/FT | 1 | DispatchHealth Holdings |
| Overlook Capital | 1 | Harbor Health Team |
| Samsara Biocapital | 1 | SUTRO BIOPHARMA |
| SV Life Sciences | 1 | SUTRO BIOPHARMA |
| Venrock | 1 | Kelonia Therapeutics |
A shared board seat: a company where filings name a Alta Partners partner and a partner at the other firm, both with a clean identity match. Not a claim either firm led or co-led the round, only that both are named on the same board.